Situation
Lung cancer patients in Kenya face considerable challenges in accessing timely and accurate diagnoses, particularly those residing on the outskirts of Nairobi. After an initial lung cancer diagnosis, patients are required to undergo additional tests, such as a lung biopsy , Histology, Immunohistochemistry (IHC) and Estimated Glomerular Filtration Rate (EGFR) test, to determine the most suitable medication. However, the process of completing these tests often extends for months due to multiple logistical and financial barriers. The costs of these tests are not reimbursed , leaving patients to bear the financial burden out of pocket. Moreover, patients or their families are responsible for transporting tissue samples to Nairobi for testing, a logistical hurdle that frequently leads to delays or abandoned efforts. Improper handling of samples during transport can result in damage, necessitating repeat biopsies. Given the invasive nature of the procedure and the limited availability of interventional radiologists, many patients are reluctant or unable to repeat the biopsy, further delaying their treatment. These obstacles create significant emotional and physical distress for patients and their families.
Solution
To address this pertinent issue, a multinational pharmaceutical company partnered with Axios International to develop a solution aimed at increasing access to diagnostic services. A Patient Support Program (PSP) was introduced in September of 2024 to improve diagnostic accessibility for lung cancer patients across Kenya. This PSP was specifically designed to address the logistical, financial, and operational barriers faced by patients. Through the PSP, tissue samples are collected directly from hospitals and securely transported to a diagnostic center in Nairobi, eliminating the burden on patients and their families to manage this themselves. By covering the costs of essential diagnostic tests, including the EGFR test, the PSP alleviates the significant financial strain that previously deterred patients from completing the diagnostic process. Furthermore, the PSP ensures proper handling of samples during transportation to prevent damage, which in turn reduces the need for repeat biopsies. Once the tests are completed, the results are promptly shared with the treating physician, enabling faster decision-making and initiation of appropriate treatment. This extensive approach has significantly streamlined the diagnostic process, reduced delays, and improved the overall experience for patients.
Results
The PSP has achieved remarkable outcomes just within its first few months of implementation. A total of 45 cases were referred to the program, and 43 patients successfully enrolled in the program and conducted/conducting confirmatory tests which include Histology, Immunohistochemistry and EGFR test with +95 percent enrollment rate. More importantly, the average timeline from referral to result was reduced to just 9.5 calendar days, a significant improvement compared to the previous delays of over months. By addressing the logistical and financial barriers that hinder access to diagnosis, the PSP has eased the burden on patients and caregivers while ensuring reliable and prompt diagnostic outcomes.
By adopting a patient-centered approach, the PSP demonstrated how strategic interventions can transform healthcare delivery and improve outcomes for lung cancer patients in Kenya.
For more information about our programs, write to us at axios@axiosint.com.
